Sandoz launches biosimilar Pyzchiva in U.S

3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara (ustekinumab), one of the most profitable drugs in the world.
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy
Sandoz launches biosimilar Pyzchiva in USA
Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, the medicine is commercially available to patients across the USA.
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy,
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge
J&J suing Samsung Bioepis over Stelara biosimilar: report
Johnson & Johnson (JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara. Read more here.
J&J sues Samsung Bioepis over Stelara biosimilar
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit, filed late on Monday in a New Jersey federal court,
Hosted on MSN3m
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract
One of those was with Samsung Bioepis in November 2024, allowing it to market a biosimilar to Stelara in February 2025.
devdiscourse13h
Biosimilar Battle: J&J Sues Samsung Over Stelara Market Intrusion
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...
STAT1d
J&J sues Samsung over a contract breach for a Stelara biosimilar
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...